Phase 4
Completed N=40
Intranasal Dexmedetomidine vs Intranasal Midazolam as Anxiolysis Prior to Pediatric Laceration Repair
Laceration · Anxiety
Source: ClinicalTrials.gov NCT02168439 ↗
Enrolled (actual)
40
Serious AEs
0.0%
Results posted
Mar 2017
Primary outcomePrimary: mYPAS Score as Completed by Researchers to Assess Anxiety — 23.3; 36.3 units on a scale
◆ Published Evidence
No publication linked
No peer-reviewed publication reporting this trial's results has been linked yet. This can indicate results are unpublished — a known publication-bias signal. We re-check periodically.
Summary
The objective of this research study is to show superiority of intranasal dexmedetomidine to intranasal midazolam as anxiolysis prior to pediatric laceration repairs.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY mYPAS Score as Completed by Researchers to Assess Anxiety |
23.3; 36.3 | — |
| SECONDARY mYPAS Scores at Other Time Points |
48.8; 47.1; 42.5; 47.1; 23.3; 35.4 | — |
| SECONDARY VAS for Anxiety as Completed by Caregiver and Observer |
3.8; 3.5; 1.7; 1.6; .7; 1.2 | — |
Eligibility Criteria
Inclusion Criteria
- Presenting to Children's Hospital of Pittsburgh of University of Pittsburgh Medical Center
- Laceration 5cm
Data sourced from ClinicalTrials.gov (NCT02168439). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.